{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:44:47Z","timestamp":1790138687730,"version":"4.0.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s11523-025-01186-w","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T11:33:50Z","timestamp":1765452830000},"page":"87-102","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Idasanutlin in Combination with Chemotherapy or Venetoclax in Pediatric and Young Adult Patients with Relapsed\/Refractory Solid Tumors (iMATRIX Idasa): Results of a Phase I\/II, Multicenter, Multi-arm Study"],"prefix":"10.1007","volume":"21","clinical-trial-number":[{"clinical-trial-number":"nct04029688","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6426-7423","authenticated-orcid":false,"given":"Alba","family":"Rubio-San-Sim\u00f3n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynley V.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Doz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaume","family":"Mora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Bielamowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadege","family":"Corradini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Langevin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aru","family":"Narendran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy A.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Michel","family":"Zwaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Gho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Cardenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecile","family":"Guizani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Breton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Wulff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Bernardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Trippett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quentin","family":"Campbell-Hewson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"issue":"2","key":"1186_CR1","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.18632\/oncotarget.23409","volume":"9","author":"V Arnhold","year":"2017","unstructured":"Arnhold V, Schmelz K, Proba J, et al. Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma. Oncotarget. 2017;9(2):2304\u201319. https:\/\/doi.org\/10.18632\/oncotarget.23409.","journal-title":"Oncotarget"},{"issue":"9","key":"1186_CR2","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1158\/1535-7163.MCT-06-0305","volume":"5","author":"E Barbieri","year":"2006","unstructured":"Barbieri E, Mehta P, Chen Z, et al. MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death. Mol Cancer Ther. 2006;5(9):2358\u201365. https:\/\/doi.org\/10.1158\/1535-7163.MCT-06-0305.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"1186_CR3","doi-asserted-by":"publisher","first-page":"114","DOI":"10.2174\/13894501113149990194","volume":"15","author":"G Barone","year":"2014","unstructured":"Barone G, Tweddle DA, Shohet JM, et al. MDM2-p53 interaction in paediatric solid tumours: preclinical rationale, biomarkers and resistance. Curr Drug Targets. 2014;15(1):114\u201323. https:\/\/doi.org\/10.2174\/13894501113149990194.","journal-title":"Curr Drug Targets"},{"issue":"11","key":"1186_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/ph14111184","volume":"14","author":"I Blanco-Luquin","year":"2021","unstructured":"Blanco-Luquin I, L\u00e1zcoz P, Celay J, Castresana JS, Enc\u00edo IJ. In vitro assessment of the role of p53 on chemotherapy treatments in neuroblastoma cell lines. Pharmaceuticals (Basel). 2021;14(11):1184. https:\/\/doi.org\/10.3390\/ph14111184.","journal-title":"Pharmaceuticals (Basel)"},{"key":"1186_CR5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2307\/2530286","volume":"38","author":"R Brookmeyer","year":"1982","unstructured":"Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics. 1982;38:29\u201341.","journal-title":"Biometrics"},{"issue":"12","key":"1186_CR6","doi-asserted-by":"publisher","first-page":"10207","DOI":"10.18632\/oncotarget.3504","volume":"6","author":"L Chen","year":"2015","unstructured":"Chen L, Rousseau RF, Middleton SA, et al. Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma. Oncotarget. 2015;6(12):10207\u201321. https:\/\/doi.org\/10.18632\/oncotarget.3504.","journal-title":"Oncotarget"},{"issue":"4_Suppl","key":"1186_CR7","doi-asserted-by":"publisher","first-page":"S1496","DOI":"10.1016\/j.annonc.2023.10.211","volume":"34","author":"TW Chen","year":"2023","unstructured":"Chen TW, Sanfilippo R, Jones RL, et al. 76MO efficacy and safety findings from MANTRA: a global, randomized, multicenter, phase III study of the MDM2 inhibitor milademetan vs trabectedin in patients with dedifferentiated liposarcomas. Ann Oncol. 2023;34(4_Suppl):S1496. https:\/\/doi.org\/10.1016\/j.annonc.2023.10.211.","journal-title":"Ann Oncol"},{"issue":"6","key":"1186_CR8","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1634\/theoncologist.2019-0615","volume":"25","author":"JW Cohen","year":"2020","unstructured":"Cohen JW, Akshintala S, Kane E, et al. A systematic review of pediatric phase I trials in oncology: toxicity and outcomes in the era of targeted therapies. Oncologist. 2020;25(6):532\u201340. https:\/\/doi.org\/10.1634\/theoncologist.2019-0615.","journal-title":"Oncologist"},{"issue":"8","key":"1186_CR9","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1158\/1535-7163.MCT-20-0710","volume":"20","author":"KM Dalton","year":"2021","unstructured":"Dalton KM, Krytska K, Lochmann TL, et al. Venetoclax-based rational combinations are effective in models of MYCN-amplified neuroblastoma. Mol Cancer Ther. 2021;20(8):1400\u201311. https:\/\/doi.org\/10.1158\/1535-7163.MCT-20-0710.","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"1186_CR10","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1182\/blood.2022016362","volume":"141","author":"NG Daver","year":"2023","unstructured":"Daver NG, Dail M, Garcia JS, et al. Venetoclax and idasanutlin in relapsed\/refractory AML: a nonrandomized, open-label phase 1b trial. Blood. 2023;141(11):1265\u201376. https:\/\/doi.org\/10.1182\/blood.2022016362.","journal-title":"Blood"},{"issue":"1","key":"1186_CR11","doi-asserted-by":"publisher","first-page":"170","DOI":"10.3324\/haematol.2018.199364","volume":"105","author":"S Demir","year":"2020","unstructured":"Demir S, Boldrin E, Sun Q, et al. Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia. Haematologica. 2020;105(1):170\u201381. https:\/\/doi.org\/10.3324\/haematol.2018.199364.","journal-title":"Haematologica"},{"issue":"4","key":"1186_CR12","doi-asserted-by":"publisher","first-page":"dju47","DOI":"10.1093\/jnci\/dju047","volume":"106","author":"SJ Diskin","year":"2014","unstructured":"Diskin SJ, Capasso M, Diamond M, et al. Rare variants in TP53 and susceptibility to neuroblastoma. J Natl Cancer Inst. 2014;106(4):dju47. https:\/\/doi.org\/10.1093\/jnci\/dju047.","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"1186_CR13","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1007\/s10637-021-01141-2","volume":"39","author":"A Italiano","year":"2021","unstructured":"Italiano A, Miller WH, Blay JY, et al. Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors. Investig New Drugs. 2021;39(6):1587\u201397. https:\/\/doi.org\/10.1007\/s10637-021-01141-2.","journal-title":"Investig New Drugs"},{"issue":"17","key":"1186_CR14","first-page":"4053","volume":"53","author":"J Imamura","year":"1993","unstructured":"Imamura J, Bartram CR, Berthold F, Harms D, Nakamura H, Koeffler HP. Mutation of the p53 gene in neuroblastoma and its relationship with N-myc amplification. Cancer Res. 1993;53(17):4053\u20138.","journal-title":"Cancer Res"},{"key":"1186_CR15","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.2147\/OTT.S172315","volume":"12","author":"A Khurana","year":"2019","unstructured":"Khurana A, Shafer DA. MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388). Onco Targets Ther. 2019;12:2903\u201310. https:\/\/doi.org\/10.2147\/OTT.S172315.","journal-title":"Onco Targets Ther"},{"issue":"21","key":"1186_CR16","first-page":"5284","volume":"53","author":"H Komuro","year":"1993","unstructured":"Komuro H, Hayashi Y, Kawamura M, et al. Mutations of the p53 gene are involved in Ewing\u2019s sarcomas but not in neuroblastomas. Cancer Res. 1993;53(21):5284\u20138.","journal-title":"Cancer Res"},{"key":"1186_CR17","doi-asserted-by":"publisher","first-page":"15026","DOI":"10.1038\/cddiscovery.2015.26","volume":"1","author":"A Lakoma","year":"2015","unstructured":"Lakoma A, Barbieri E, Agarwal S, et al. The MDM2 small-molecule inhibitor RG7388 leads to potent tumor inhibition in p53 wild-type neuroblastoma. Cell Death Discov. 2015;1:15026. https:\/\/doi.org\/10.1038\/cddiscovery.2015.26.","journal-title":"Cell Death Discov"},{"issue":"1_Suppl","key":"1186_CR18","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1182\/blood.V130.Suppl_1.254.254","volume":"130","author":"J Mascarenhas","year":"2017","unstructured":"Mascarenhas J, Lu M, Virtgaym E, et al. Open label phase I study of single agent oral RG7388 (idasanutlin) in patients with polycythemia vera and essential thrombocythemia. Blood. 2017;130(1_Suppl):254. https:\/\/doi.org\/10.1182\/blood.V130.Suppl_1.254.254.","journal-title":"Blood"},{"issue":"6","key":"1186_CR19","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1182\/blood.2018893545","volume":"134","author":"J Mascarenhas","year":"2019","unstructured":"Mascarenhas J, Lu M, Kosiorek H, et al. Oral idasanutlin in patients with polycythemia vera. Blood. 2019;134(6):525\u201333. https:\/\/doi.org\/10.1182\/blood.2018893545.","journal-title":"Blood"},{"issue":"4","key":"1186_CR20","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1182\/bloodadvances.2021006043.","volume":"6","author":"J Mascarenhas","year":"2022","unstructured":"Mascarenhas J, Passamonti F, Burbury K, et al. The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study. Blood Adv. 2022;6(4):1162\u201374. https:\/\/doi.org\/10.1182\/bloodadvances.2021006043.","journal-title":"Blood Adv"},{"issue":"12","key":"1186_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2011.129","volume":"2","author":"M Michaelis","year":"2011","unstructured":"Michaelis M, Rothweiler F, Barth S, et al. Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells. Cell Death Dis. 2011;2(12):e243. https:\/\/doi.org\/10.1038\/cddis.2011.129.","journal-title":"Cell Death Dis"},{"key":"1186_CR22","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ejca.2020.05.010","volume":"136","author":"L Moreno","year":"2020","unstructured":"Moreno L, Barone G, DuBois SG, et al. Accelerating drug development for neuroblastoma: summary of the second neuroblastoma drug development strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma. Eur J Cancer. 2020;136:52\u201368. https:\/\/doi.org\/10.1016\/j.ejca.2020.05.010.","journal-title":"Eur J Cancer"},{"key":"1186_CR23","unstructured":"Morgenstern D, Barone G, Federico S, et al. Final results from a phase 1 study of venetoclax in pediatrics and young adults with relapsed\/refractory neuroblastoma. SIOP Abstract EP286. Pediatr Blood Cancer 2024; S293."},{"issue":"3","key":"1186_CR24","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s00280-018-3521-z","volume":"81","author":"J Nemunaitis","year":"2018","unstructured":"Nemunaitis J, Young A, Ejadi S, et al. Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2018;81(3):529\u201337. https:\/\/doi.org\/10.1007\/s00280-018-3521-z.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"1186_CR25","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a026336","volume":"6","author":"JD Oliner","year":"2016","unstructured":"Oliner JD, Saiki AY, Caenepeel S. The role of MDM2 amplification and overexpression in tumorigenesis. Cold Spring Harb Perspect Med. 2016;6(6):a026336. https:\/\/doi.org\/10.1101\/cshperspect.a026336.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"10","key":"1186_CR26","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1016\/j.ejca.2013.02.028","volume":"49","author":"X Paoletti","year":"2013","unstructured":"Paoletti X, Geoerger B, Doz F, Baruchel A, Lokiec F, Le Tourneau C. A comparative analysis of paediatric dose-finding trials of molecularly targeted agent with adults\u2019 trials. Eur J Cancer. 2013;49(10):2392\u2013402. https:\/\/doi.org\/10.1016\/j.ejca.2013.02.028.","journal-title":"Eur J Cancer"},{"issue":"1","key":"1186_CR27","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00280-019-03851-0","volume":"84","author":"Z P\u00e1pai","year":"2019","unstructured":"P\u00e1pai Z, Chen LC, Da Costa D, et al. A single-center, open-label study investigating the excretion balance, pharmacokinetics, metabolism, and absolute bioavailability of a single oral dose of [14C]-labeled idasanutlin and an intravenous tracer dose of [13C]-labeled idasanutlin in a single cohort of patients with solid tumors. Cancer Chemother Pharmacol. 2019;84(1):93\u2013103. https:\/\/doi.org\/10.1007\/s00280-019-03851-0.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"1186_CR28","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1177\/1947601911409745","volume":"2","author":"EM Pinto","year":"2011","unstructured":"Pinto EM, Ribeiro RC, Figueiredo BC, Zambetti GP. TP53-associated pediatric malignancies. Genes Cancer. 2011;2(4):485\u201390. https:\/\/doi.org\/10.1177\/1947601911409745.","journal-title":"Genes Cancer"},{"issue":"13_Supplement","key":"1186_CR29","doi-asserted-by":"publisher","first-page":"CT027","DOI":"10.1158\/1538-7445.AM2018-CT027","volume":"78","author":"P Roxburgh","year":"2018","unstructured":"Roxburgh P, Currie D, Morrison P, et al. Abstract CT027: safety, pharmacokinetics (PK) and pharmacodynamics (PD) of idasanutlin (idasa), combined with abiraterone (abi)\/prednisolone (pred) or enzalutamide (enza) in castrate resistant prostate cancer (CRPC). Cancer Res. 2018;78(13_Supplement):CT027. https:\/\/doi.org\/10.1158\/1538-7445.AM2018-CT027.","journal-title":"Cancer Res"},{"issue":"4","key":"1186_CR30","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/jcph.821","volume":"57","author":"AH Salem","year":"2017","unstructured":"Salem AH, Agarwal SK, Dunbar M, et al. Pharmacokinetics of venetoclax, a novel BCL-2 inhibitor, in patients with relapsed or refractory chronic lymphocytic leukemia or non-Hodgkin lymphoma. J Clin Pharmacol. 2017;57(4):484\u201392. https:\/\/doi.org\/10.1002\/jcph.821.","journal-title":"J Clin Pharmacol"},{"key":"1186_CR31","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ejca.2020.01.027","volume":"130","author":"NA Schubert","year":"2020","unstructured":"Schubert NA, Lowery CD, Bergthold G, et al. Systematic target actionability reviews of preclinical proof-of-concept papers to match targeted drugs to paediatric cancers. Eur J Cancer. 2020;130:168\u201381. https:\/\/doi.org\/10.1016\/j.ejca.2020.01.027.","journal-title":"Eur J Cancer"},{"issue":"11","key":"1186_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10110396","volume":"10","author":"L Skalniak","year":"2018","unstructured":"Skalniak L, Kocik J, Polak J, et al. Prolonged idasanutlin (RG7388) treatment leads to the generation of p53-mutated cells. Cancers (Basel). 2018;10(11):396. https:\/\/doi.org\/10.3390\/cancers10110396.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"1186_CR33","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1073\/pnas.0405495102","volume":"102","author":"A Slack","year":"2005","unstructured":"Slack A, Chen Z, Tonelli R, et al. The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. Proc Natl Acad Sci U S A. 2005;102(3):731\u20136. https:\/\/doi.org\/10.1073\/pnas.0405495102.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"22","key":"1186_CR34","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1093\/jnci\/djp355","volume":"101","author":"T Van Maerken","year":"2009","unstructured":"Van Maerken T, Ferdinande L, Taildeman J, et al. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53. J Natl Cancer Inst. 2009;101(22):1562\u201374. https:\/\/doi.org\/10.1093\/jnci\/djp355.","journal-title":"J Natl Cancer Inst"},{"issue":"34","key":"1186_CR35","doi-asserted-by":"publisher","first-page":"57047","DOI":"10.18632\/oncotarget.18982","volume":"8","author":"A Van Goethem","year":"2017","unstructured":"Van Goethem A, Yigit N, Moreno-Smith M, et al. Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastoma. Oncotarget. 2017;8(34):57047\u201357. https:\/\/doi.org\/10.18632\/oncotarget.18982.","journal-title":"Oncotarget"},{"issue":"6","key":"1186_CR36","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1158\/1535-7163.MCT-20-0666","volume":"20","author":"L Vernooij","year":"2021","unstructured":"Vernooij L, Bate-Eya LT, Alles LK, et al. High-throughput screening identifies idasanutlin as a resensitizing drug for venetoclax-resistant neuroblastoma cells. Mol Cancer Ther. 2021;20(6):1161\u201372. https:\/\/doi.org\/10.1158\/1535-7163.MCT-20-0666.","journal-title":"Mol Cancer Ther"},{"issue":"21","key":"1186_CR37","first-page":"5269","volume":"53","author":"K Vogan","year":"1993","unstructured":"Vogan K, Bernstein M, Leclerc JM, et al. Absence of p53 gene mutations in primary neuroblastomas. Cancer Res. 1993;53(21):5269\u201373.","journal-title":"Cancer Res"},{"key":"1186_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114334","volume":"236","author":"S Wang","year":"2022","unstructured":"Wang S, Chen FE. Small-molecule MDM2 inhibitors in clinical trials for cancer therapy. Eur J Med Chem. 2022;236:114334. https:\/\/doi.org\/10.1016\/j.ejmech.2022.114334.","journal-title":"Eur J Med Chem"},{"issue":"11","key":"1186_CR39","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1182\/blood.2022018739","volume":"141","author":"ES Wang","year":"2023","unstructured":"Wang ES. MDM2 and BCL-2: to p53 or not to p53? Blood. 2023;141(11):1237\u20138. https:\/\/doi.org\/10.1182\/blood.2022018739.","journal-title":"Blood"},{"issue":"3","key":"1186_CR40","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1124\/pharmrev.123.001026","volume":"76","author":"W Wang","year":"2024","unstructured":"Wang W, Albadari N, Du Y, et al. MDM2 inhibitors for cancer therapy: the past, present, and future. Pharmacol Rev. 2024;76(3):414\u201353. https:\/\/doi.org\/10.1124\/pharmrev.123.001026.","journal-title":"Pharmacol Rev"},{"issue":"3","key":"1186_CR41","doi-asserted-by":"publisher","first-page":"429","DOI":"10.2217\/fon.09.176","volume":"6","author":"J Wolter","year":"2010","unstructured":"Wolter J, Angelini P, Irwin M. P53 family: therapeutic targets in neuroblastoma. Future Oncol. 2010;6(3):429\u201344. https:\/\/doi.org\/10.2217\/fon.09.176.","journal-title":"Future Oncol"},{"issue":"10","key":"1186_CR42","first-page":"1023","volume":"2","author":"H Yang","year":"2003","unstructured":"Yang H, Filipovic Z, Brown D, Breit SN, Vassilev LT. Macrophage inhibitory cytokine-1: a novel biomarker for p53 pathway activation. Mol Cancer Ther. 2003;2(10):1023\u20139.","journal-title":"Mol Cancer Ther"},{"key":"1186_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2020.106489","volume":"100","author":"K Yee","year":"2021","unstructured":"Yee K, Papayannidis C, Vey N, et al. Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: results from an idasanutlin phase 1\/1b study\u22c6. Leuk Res. 2021;100:106489. https:\/\/doi.org\/10.1016\/j.leukres.2020.106489.","journal-title":"Leuk Res"},{"issue":"1","key":"1186_CR44","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13045-022-01314-3","volume":"15","author":"H Zhu","year":"2022","unstructured":"Zhu H, Gao H, Ji Y, et al. Targeting p53-MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials. J Hematol Oncol. 2022;15(1):91. https:\/\/doi.org\/10.1186\/s13045-022-01314-3.","journal-title":"J Hematol Oncol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01186-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-025-01186-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01186-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T16:47:11Z","timestamp":1771692431000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-025-01186-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1186"],"URL":"https:\/\/doi.org\/10.1007\/s11523-025-01186-w","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,11]]},"assertion":[{"value":"4 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"C.G. was an employee of F. Hoffman-La Roche Ltd. at the time of study conduct. A.C., S.F., V.B., B.W., and R.B. are employees of and stockholders in F. Hoffmann-La Roche Ltd\/Genentech, Inc. F.D. is a consultant for Servier, Ipsen Pharma, and Novartis; has received research funding from Onxeo\/Valerio and SynthInnove; and has received travel expenses from Roche. M.Z. is a consultant for Beigene, Taiho Oncology, Incyte, Novartis, Sutro, Syndax, and Sanofi and has institutional research funding from Takeda, Pfizer, Kura Oncology, Daiichi-Sankyo, and Abbvie. A.R., L.M., J.M., K.B., N.C., A.L., A.N., A.S., D.G., T.T., and Q.C. declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was performed in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Written informed consent was obtained from parents, patients, or legal representatives.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"Qualified researchers may request access to individual patient level data through the clinical study data request platform (\n                      \n                      ). Further details on Roche\u2019s criteria for eligible studies are available here:\n                      \n                      . For further details on Roche\u2019s Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here:\n                      \n                      .","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors contributed to collection and assembly of data and to data analysis and interpretation. All authors critically reviewed the manuscript, provided final approval, and agreed to be accountable for all aspects of the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}